PT - JOURNAL ARTICLE AU - Karger, Amy B. AU - Brien, James D. AU - Christen, Jayne M. AU - Dhakal, Santosh AU - Kemp, Troy J. AU - Klein, Sabra L. AU - Pinto, Ligia A. AU - Premkumar, Lakshmanane AU - Roback, John D. AU - Binder, Raquel A. AU - Boehme, Karl W. AU - Boppana, Suresh AU - Crawford, James M. AU - Daiss, John L. AU - Dupuis, Alan P. AU - Espino, Ana M. AU - Forconi, Catherine AU - Forrest, J. Craig AU - Girardin, Roxie C. AU - Haddad, Natalie S. AU - Heaney, Christopher D. AU - Hunt, Danielle T. AU - Kennedy, Joshua L. AU - King, Christopher L. AU - Kruczynski, Kate AU - LaBaer, Joshua AU - Lee, F. Eun-Hyung AU - Lee, William T. AU - Liu, Shan-Lu AU - Lozanski, Gerard AU - Moormann, Ann M. AU - Murugan, Vel AU - Okoye, Nkemakonam C. AU - Pantoja, Petraleigh AU - Payne, Anne F. AU - Park, Jin AU - Pinninti, Swetha AU - Pinto, Amelia K. AU - Pisanic, Nora AU - Qiu, Ji AU - Sariol, Carlos A. AU - Song, Lusheng AU - Steffen, Tara L. AU - Stone, E. Taylor AU - Styer, Linda M. AU - Suthar, Mehul S. AU - Thomas, Stefani N. AU - Thyagarajan, Bharat AU - Yates, Jennifer L. AU - Sobhani, Kimia TI - The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization AID - 10.1101/2022.02.27.22271399 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.27.22271399 4099 - http://medrxiv.org/content/early/2022/03/01/2022.02.27.22271399.short 4100 - http://medrxiv.org/content/early/2022/03/01/2022.02.27.22271399.full AB - Background In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and “to develop, validate, improve, and implement serological testing and associated technologies.” SeroNet is comprised of 25 participating research institutions partnering with the Frederick National Laboratory for Cancer Research (FNLCR) and the SeroNet Coordinating Center. Since its inception, SeroNet has supported collaborative development and sharing of COVID-19 serological assay procedures and has set forth plans for assay harmonization.Methods To facilitate collaboration and procedure sharing, a detailed survey was sent to collate comprehensive assay details and performance metrics on COVID-19 serological assays within SeroNet. In addition, FNLCR established a protocol to calibrate SeroNet serological assays to reference standards, such as the U.S. SARS-CoV-2 serology standard reference material and First WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin (20/136), to facilitate harmonization of assay reporting units and cross-comparison of study data.Results SeroNet institutions reported development of a total of 27 ELISA methods, 13 multiplex assays, 9 neutralization assays, and use of 12 different commercial serological methods. FNLCR developed a standardized protocol for SeroNet institutions to calibrate these diverse serological assays to reference standards.Conclusions SeroNet institutions have established a diverse array of COVID-19 serological assays to study the immune response to SARS-CoV-2 virus and vaccines. Calibration of SeroNet serological assays to harmonize results reporting will facilitate future pooled data analyses and study cross-comparisons.Competing Interest StatementA.B.K. is a consultant for Roche Diagnostics and has received research support from Siemens Healthcare Diagnostics and Kyowa Kirin Pharmaceutical Development. J.D.B., A.K.P., E.T.S., and T.L.S. have received research support from Altimmune. J.D.R. and M.S.S. are co-inventors on a patent filed by Emory University covering the serology assay described in this manuscript. M.S.S. serves on the advisory board for Moderna and Ocugen. F.E.L. is the founder of MicroB-plex, Inc. J.L.D. is the CSO of MicroB-plex, Inc. N.S.H. has been a senior scientist at MicroB-plex, Inc. F.E.L. has research grants from the Gates Foundation and Genentech, is on the SAB of Be Biopharma, Inc., and received royalties from BLI, Inc., as an inventor for the plasma cell survival media. S.B. has research support from Merck and Pfizer, and is a member of the CMV Vaccine Advisory Committees of Merck and Moderna. S.P. has research support from Moderna. All remaining authors report no relevant conflicts of interest.Funding StatementThis study was funded by: U54CA260591, U01CA260584, U01CA260469, U54CA260543, U54CA260560, U54CA260582, U54CA260492, U01CA260541, U01CA261277, U01CA261277, U01CA260526, U01CA261276, U01CA260539, U01CA260513, U01CA260462, CBC21X089, CBC21X090, CBC21X091, CBC21X092Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.